As tumor suppressors and activated oncogenes also contribute to drug and radiation resistance [26,27,28], we also tested whether mutations in the tumor suppressor gene TP53 or the H-RAS, K–RAS, and N-RAS genes as well as the mRNA expression of the epidermal growth factor receptor gene (EGFR) are associated with cellular response to scopoletin. This evidence concerns the gene NRAS and neoplasm.